Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Carcinoma, Non-Small-Cell Lung 372Neoplasms 325Neoplasm Metastasis 290Leukemia, Myeloid, Acute 282Breast Neoplasms 275Colorectal Neoplasms 235Melanoma 197Ovarian Neoplasms 192Recurrence 185Multiple Myeloma 179Prostatic Neoplasms 157Pancreatic Neoplasms 157Lung Neoplasms 157Squamous Cell Carcinoma of Head and Neck 150Lymphoma, Non-Hodgkin 146Glioblastoma 145Triple Negative Breast Neoplasms 119Myelodysplastic Syndromes 117Carcinoma, Renal Cell 112Stomach Neoplasms 110Advanced Solid Tumors 108Glioma 106Precursor Cell Lymphoblastic Leukemia-Lymphoma 105Lymphoma 104Brain Neoplasms 103Lymphoma, Large B-Cell, Diffuse 102Lymphoma, B-Cell 99Carcinoma, Hepatocellular 95Endometrial Neoplasms 93Lymphoma, Follicular 90

Interventions

poly ICLC 1Nivolumab 1Injections 1Decitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Anemia, Refractory × 1 year × Clear all
NCT03358719 2026-02-27

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Roswell Park Cancer Institute

Phase 1 Completed
8 enrolled 9 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡